Research Article
BibTex RIS Cite

A Glance into Botulinum Toxin Outpatient Clinic in Movement Disorders Practice: Self Experience

Year 2019, Volume: 21 Issue: 3, 162 - 165, 30.12.2019

Yıldız Değirmenci

https://doi.org/10.18678/dtfd.559329

Abstract

Aim: Aim of this study is to determine socio-demographic and disease features of patients who underwent Botulinum toxin injections, and to present our clinical experience via documenting intervals of Botulinum toxin injections and effect-side effect profiles.

Material and Methods: Socio-demographic features of patients and characteristic features of Botulinum toxin treatment were recorded. The diagnosis of the patients who underwent Botulinum toxin injections, disease durations and the onset of Botulinum toxin treatments were investigated. Possible side-effects were recorded.

Results: Thirty-two patients (20 men, 12 women) with the diagnosis of various types of movement disorders were enrolled the study. Mean age of patients was 60.65±14.40 years (range= 22-83 years). Diagnosis of the patients who underwent Botulinum toxin injections were cervical dystonia, blepharospasm, clonic hemifacial spasm, focal hand dystonia/writer’s cramp, oromandibular dystonia, and dystonic tremor. All patients had repetitive Botulinum toxin injections. There were no remarkable adverse effects, other than mild temporary bruises in injection site in two patients with blepharospasm.

Conclusion: Botulinum toxin is an important treatment option in patients with focal dystonia. Botulinum toxin as a neurotoxin of Clostridium botulinum bacteria, suppresses muscle contractions via inhibiting acetylcholine release to the synaptic gap. This reversible effect lasts three to four months due to the neuronal sprouting. It is important to share clinical experiences, data of Botulinum toxin outpatient clinics or clinics from the movement disorders perspective to increase awareness of Botulinum toxin effectivity in patients with movement disorders, focal dystonia particularly.

Keywords

Botulinum toxin movement disorders focal distonia

References

  • Jankovic J. An update on new and unique uses of botulinum toxin in movement disorders. Toxicon. 2018;147:84-8.
  • Pearce JMS. A note on the use of botulinum toxin. J Neurol Neurosurg Psychiatry. 1999;67(2):230.
  • Thakker MM, Rubin PA. Pharmacology and clinical applications of botulinum toxins A and B. Int Ophthalmol Clin. 2004;44(3):147-63.
  • Tater P, Pandey S. Botulinum toxin in movement disorders. Neurol India. 2018;66(Suppl):S79-89.
  • Gronseth GS, Woodroffe LM, Getchius TSD. Clinical Practice Guidelines Process Manual. 2011 ed. St. Paul, MN: The American Academy of Neurology; 2011.
  • Chen S. Clinical uses of botulinum neurotoxins: current indications, limitations and future developments. Toxins (Basel). 2012;4(10):913-39.
  • Skogseid IM. Dystonia--new advances in classification, genetics, pathophysiology and treatment. Acta Neurol Scand Suppl. 2014;(198):13-9.
  • Drummond GT, Hinz BJ. Botulinum toxin for blepharospasm and hemifacial spasm: stability of duration of effect and dosage over time. Can J Ophthalmol. 2001;36(7):398-403.
  • Poewe W, Wissel J. Use of botulinum toxin in the treatment of cervical dystonia. Baillieres Clin Neurol. 1993; 2(1):179-85.
  • Lungu C, Karp BI, Alter K, Zolbrod R, Hallett M. Long-term follow-up of botulinum toxin therapy for focal hand dystonia: outcome at 10 years or more. Mov Disord. 2011;26(4):750-3.
  • Karp BI, Alter K. Botulinum toxin treatment of blepharospasm, orofacial/oromandibular dystonia, and hemifacial spasm. Semin Neurol. 2016;36(1):84-91.
  • Jankovic J. Botulinum toxin: state of art. Mov Disord. 2017;32(8):1131-8.
  • Lizarraga KJ, Al-Shorafat D, Fox S. Update on current and emerging therapies for dystonia. Neurodegener Dis Manag. 2019;9(3):135-47.
  • Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86(19):1818-26.
  • Papapetropoulos S, Singer C. Botulinum toxin in movement disorders. Semin Neurol. 2007;27(2):183-94.
  • Nigam PK, Nigam A. Botulinum toxin. Indian J Dermatol. 2010;55(1):8-14.
  • Yiannakopoulou E. Serious and long-term adverse events associated with the therapeutic and cosmetic use of botulinum toxin. Pharmacology. 2015;95(1-2):65-9.

Hareket Bozuklukları Pratiğinde Botulinum Toksin Polikliniğine Bakış: Kişisel Deneyim

Year 2019, Volume: 21 Issue: 3, 162 - 165, 30.12.2019

Yıldız Değirmenci

https://doi.org/10.18678/dtfd.559329

Abstract

Amaç: Bu çalışmanın amacı Botulinum toksin enjeksiyonu uygulanan hastaların sosyodemografik özellikleri ve hastalık özelliklerinin belirlenmesi, ve Botulinum toksin uygulama aralıkları ile etki ve yan etki profillerini dokümante ederek klinik deneyimimizin sunulmasıdır.

Gereç ve Yöntemler: Hastaların sosyodemografik özellikleri ve Botulinum toksin tedavisinin karakteristik özellikleri kaydedilmiştir. Botulinum toksin enjeksiyonu yapılan hastaların hastalık tanıları, hastalık süreleri ve Botulinum toksin tedavisine başlama süreleri incelenmiştir. Olası yan etkiler kaydedilmiştir.

Bulgular: Çeşitli hareket hastalıkları tanısı almış otuz iki hasta (20 erkek, 12 kadın) çalışmaya dahil edilmiştir. Hastaların yaş ortalaması 60.65±14.40 yaştır (aralık= 22-83 yaş). Botulinum toksin enjeksiyonu uygulanan hastaların tanıları servikal distoni, blefarospazm, klonik hemifasiyal spazm, fokal el distonisi/yazıcı krampı, oromandibular distoni ve distonik tremordur. Tüm hastalara tekrarlayan Botulinum nörotoksin enjeksiyonları yapılmıştır. İki blefarospazm hastasında enjeksiyon bölgesinde izlenen hafif morluklar dışında, hastalarda belirgin yan etki görülmemiştir.

Sonuç: Botulinum toksin fokal distonili hastalarda önemli bir tedavi seçeneğidir. Clostridium botulinum bakterisinin nörotoksini olan Botulinum nörotoksin, sinaptik aralığa asetilkolin salınımını engelleyerek kas kasılmasını baskılamak üzere çalışır. Geri dönüşümlü olan bir etki ile nöronal filizlenmenin süresiyle ilişkili olarak yaklaşık üç ila dört ay kadar sürmektedir. Özellikle fokal distoni gibi hareket bozuklukları hastalarında Botulinum toksin etkinliğine ilişkin farkındalığı arttırmak amacıyla ve hareket hastalıkları perspektifinden Botulinum toksin poliklinik veya kliniklerinin klinik deneyimlerini ve verilerini paylaşmak önem arz etmektedir.

Keywords

Botulinum toksin hareket bozuklukları fokal distoni

References

  • Jankovic J. An update on new and unique uses of botulinum toxin in movement disorders. Toxicon. 2018;147:84-8.
  • Pearce JMS. A note on the use of botulinum toxin. J Neurol Neurosurg Psychiatry. 1999;67(2):230.
  • Thakker MM, Rubin PA. Pharmacology and clinical applications of botulinum toxins A and B. Int Ophthalmol Clin. 2004;44(3):147-63.
  • Tater P, Pandey S. Botulinum toxin in movement disorders. Neurol India. 2018;66(Suppl):S79-89.
  • Gronseth GS, Woodroffe LM, Getchius TSD. Clinical Practice Guidelines Process Manual. 2011 ed. St. Paul, MN: The American Academy of Neurology; 2011.
  • Chen S. Clinical uses of botulinum neurotoxins: current indications, limitations and future developments. Toxins (Basel). 2012;4(10):913-39.
  • Skogseid IM. Dystonia--new advances in classification, genetics, pathophysiology and treatment. Acta Neurol Scand Suppl. 2014;(198):13-9.
  • Drummond GT, Hinz BJ. Botulinum toxin for blepharospasm and hemifacial spasm: stability of duration of effect and dosage over time. Can J Ophthalmol. 2001;36(7):398-403.
  • Poewe W, Wissel J. Use of botulinum toxin in the treatment of cervical dystonia. Baillieres Clin Neurol. 1993; 2(1):179-85.
  • Lungu C, Karp BI, Alter K, Zolbrod R, Hallett M. Long-term follow-up of botulinum toxin therapy for focal hand dystonia: outcome at 10 years or more. Mov Disord. 2011;26(4):750-3.
  • Karp BI, Alter K. Botulinum toxin treatment of blepharospasm, orofacial/oromandibular dystonia, and hemifacial spasm. Semin Neurol. 2016;36(1):84-91.
  • Jankovic J. Botulinum toxin: state of art. Mov Disord. 2017;32(8):1131-8.
  • Lizarraga KJ, Al-Shorafat D, Fox S. Update on current and emerging therapies for dystonia. Neurodegener Dis Manag. 2019;9(3):135-47.
  • Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86(19):1818-26.
  • Papapetropoulos S, Singer C. Botulinum toxin in movement disorders. Semin Neurol. 2007;27(2):183-94.
  • Nigam PK, Nigam A. Botulinum toxin. Indian J Dermatol. 2010;55(1):8-14.
  • Yiannakopoulou E. Serious and long-term adverse events associated with the therapeutic and cosmetic use of botulinum toxin. Pharmacology. 2015;95(1-2):65-9.
There are 17 citations in total.

Details

Primary Language English
Subjects Clinical Sciences
Journal Section Research Article
Authors

Yıldız Değirmenci 0000-0002-8584-5488

Publication Date December 30, 2019
Submission Date April 30, 2019
Published in Issue Year 2019 Volume: 21 Issue: 3

Cite

APA Değirmenci, Y. (2019). A Glance into Botulinum Toxin Outpatient Clinic in Movement Disorders Practice: Self Experience. Duzce Medical Journal, 21(3), 162-165. https://doi.org/10.18678/dtfd.559329
AMA Değirmenci Y. A Glance into Botulinum Toxin Outpatient Clinic in Movement Disorders Practice: Self Experience. Duzce Med J. December 2019;21(3):162-165. doi:10.18678/dtfd.559329
Chicago Değirmenci, Yıldız. “A Glance into Botulinum Toxin Outpatient Clinic in Movement Disorders Practice: Self Experience”. Duzce Medical Journal 21, no. 3 (December 2019): 162-65. https://doi.org/10.18678/dtfd.559329.
EndNote Değirmenci Y (December 1, 2019) A Glance into Botulinum Toxin Outpatient Clinic in Movement Disorders Practice: Self Experience. Duzce Medical Journal 21 3 162–165.
IEEE Y. Değirmenci, “A Glance into Botulinum Toxin Outpatient Clinic in Movement Disorders Practice: Self Experience”, Duzce Med J, vol. 21, no. 3, pp. 162–165, 2019, doi: 10.18678/dtfd.559329.
ISNAD Değirmenci, Yıldız. “A Glance into Botulinum Toxin Outpatient Clinic in Movement Disorders Practice: Self Experience”. Duzce Medical Journal 21/3 (December 2019), 162-165. https://doi.org/10.18678/dtfd.559329.
JAMA Değirmenci Y. A Glance into Botulinum Toxin Outpatient Clinic in Movement Disorders Practice: Self Experience. Duzce Med J. 2019;21:162–165.
MLA Değirmenci, Yıldız. “A Glance into Botulinum Toxin Outpatient Clinic in Movement Disorders Practice: Self Experience”. Duzce Medical Journal, vol. 21, no. 3, 2019, pp. 162-5, doi:10.18678/dtfd.559329.
Vancouver Değirmenci Y. A Glance into Botulinum Toxin Outpatient Clinic in Movement Disorders Practice: Self Experience. Duzce Med J. 2019;21(3):162-5.
 Download Cover Image
Creative Commons License
Duzce Medical Journal is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.